Pre-market Hot Trades in US Stocks
Zenas Biopharma, down 8.07% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Top Gainers in Pre-market US Stocks
Cyclerion Therapeutics is up 42.03% in pre-market trading. Based on recent news,
<ol>
<li>
On January 5, Cyclerion Therapeutics announced a strategic agreement with MedSteer and is advancing the Phase 2 proof-of-concept study for CYC-126 to treat resistant depression. Following this announcement, the market expressed optimism about the company's prospects, driving the stock price significantly higher.
</li>
<li>
On January 5, the company stated it plans to complete equipment integration and finalize its drug delivery system in the second half of this year to initiate the Phase 2 proof-of-concept study for CYC-126. This progress further boosted investor confidence, propelling the stock price upward. The biopharmaceutical industry has performed strongly recently, with investors focusing on new drug development progress.
</li>
</ol>
Aeva Tech is up 31.47% in pre-market trading. Based on recent news,
<ol>
<li>
On January 6, Aeva Technologies announced it will provide 4D LiDAR sensors for Nvidia's Hyperion platform. This platform is a reference architecture and development platform for autonomous vehicles, combining high-performance computing, sensor suites, and end-to-end software. This news drove Aeva's stock price up 33.9% in pre-market trading.
</li>
<li>
On January 5, Aeva Technologies released a statement emphasizing its collaboration with Nvidia, noting the goal to start vehicle production projects in 2028. This announcement further enhanced market confidence in Aeva's future growth.
</li>
<li>
In 2025, Aeva's stock price nearly tripled, indicating market recognition of its technology and business model. The autonomous driving industry has broad prospects, and technological innovation is key.
</li>
</ol>
VS MEDIA is up 25.45% in pre-market trading. Based on recent key news:
<ol>
<li>
On January 6, VS Media announced the postponement of the effective date for its reverse stock split of Class A common shares. Due to the failure to obtain necessary regulatory approvals in time, the split date was postponed from January 9 to January 12. This news led to a change in market expectations for the company's stock price, driving it upward.
</li>
<li>
On January 5, VS Media announced in Hong Kong that the effective date for its reverse stock split has been adjusted to January 12. The company faced unexpected regulatory approval challenges, and the adjusted split date created new expectations for the company's future stock price movements, further impacting the stock price.
</li>
<li>
On January 2, the company announced a 1-for-20 share consolidation. This move triggered a re-evaluation of the company's stock price in the market, leading to price volatility. The digital creator industry faces regulatory challenges
</li>
</ol>

ZBIO

Zenas Biopharma pre-market down 8.07%; Cyclerion Therapeutics pre-market up 42.03%; Aeva Tech pre-market up 31.47%; VS MEDIA pre-market up 25.45%

Pre-market hot trades in US stocks: Zenas Biopharma pre-market down 8.07%, sector trends causing market fluctuations?